1 / 12

Step 3: Verify P-drug

Step 3: Verify P-drug. The 2010 CPG on CAP recommends the use of the following for MR-CAP: IV non-antipseudomonal β-lactam (BLIC, cephalosporin or carbapenem) + an extended macrolide OR IV non-antipseudomonal β-lactam + fluoroquinolone.

roscoe
Download Presentation

Step 3: Verify P-drug

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Step 3: Verify P-drug • The 2010 CPG on CAP recommends the use of the following for MR-CAP: • IV non-antipseudomonal β-lactam (BLIC, cephalosporin or carbapenem) + an extended macrolide OR • IV non-antipseudomonal β-lactam + fluoroquinolone

  2. Patient’s hypersensitivity to β-lactam antibiotics, however compels us to choose monotherapy using a respiratory fluoroquinolone such as levofloxacin or moxifloxacin

  3. Decision to chose Fluoroquinolone over an extended macrolide • A respiratory fluoroquinolone as monotherapy was chosen over an extended macrolide due to the severity of the patient's situation. • Presence of sepsis and concomittant uncontrolled diabetes in the patient compels us to choose a respiratory fluoroquinolone due to its stronger activity against the suspected pathogens.

  4. Decision to choose Levofloxacin over Moxifloxacin • Though Levofloxacin and Moxifloxacin shows equal efficacy in the treatment of CAP-MR, Levofloxacin is chosen due to its more affordable price.

  5. Dosage • Patient should be started with 750mg IV Levothyroxine q24 hour. • Assessment should be done after 3days so that parenteral therapy can be descalated to oral therapy once patient starts improving. • Nonresponse to therapy is an indication to examine Culture-Sensitivity of the etiologic agent and proper adminstration of adequate antimicrobial

More Related